1,476
Views
3
CrossRef citations to date
0
Altmetric
Articles

An optimized agonist peptide of protease-activated receptor 4 and its use in a validated platelet-aggregation assay

ORCID Icon, ORCID Icon, , , , , & show all
Pages 979-986 | Received 07 Mar 2022, Accepted 08 Mar 2022, Published online: 28 Mar 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Samira Merali, Zhaoqing Wang, Charles Frost, Stephanie Meadows-Shropshire, Dara Hawthorne, Jing Yang & Dietmar Seiffert. (2023) First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants. Platelets 34:1.
Read now
Samira Merali, Zhaoqing Wang, Charles Frost, Mario Callejo, Michael Hedrick, Lester Hui, Stephanie Meadows Shropshire, Ke Xu, Michel Bouvier, Mary M. DeSouza & Jing Yang. (2022) New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans. Platelets 33:7, pages 969-978.
Read now

Articles from other publishers (1)

Swapnil Sanmukh, Nilton Dos Santos, Caroline Barquilha, Márcio De Carvalho, Patricia Dos Reis, Flávia Delella, Hernandes Carvalho, Dorota Latek, Tamás Fehér & Sérgio Felisbino. (2023) Bacterial RNA virus MS2 exposure increases the expression of cancer progression genes in the LNCaP prostate cancer cell line. Oncology Letters 25:2.
Crossref